在疫苗研发领域,Moderna 公司一直备受瞩目。然而,近期该公司的流感/新冠联合疫苗 mRNA - 1083 却遭遇诸多挑战,不仅研发优先级被调整,审批进程也出现延迟。这一系列变化背后,反映出公司在成本控制、市场需求以及监管要求之间的艰难权衡。联合疫苗研发计划重大调整Moderna 公司在削减运营成本的大背景下,对流感 / 新冠联合疫苗 mRNA - 1083 的研发策略做出了重大调整。这家总部...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.